Skip to main content
. 2017 Nov 2;7:260. doi: 10.3389/fonc.2017.00260

Table 3.

Adverse events.

Adverse events BCG n (%) Gemcitabine n (%) p-Value
Cystitis 6 (11%) 2 (3%) 0.14
Urosepsis 5 (9%) 0 0.06
Suprapubic discomfort 3 (5%) 2 (3%) 0.66
Hematuria 5 (9%) 0 0.06
Systemic BCG infection 4 (7%) 0 0.11

Total 23 (44%) 4 (7%) <0.05

GEM, intravesical gemcitabine; BCG, intravesical bacillus Calmette–Guérin.